胎盘生长因子及其受体系统在视网膜血管疾病中的作用
胎盘生长因子(PlGF)是VEGF家族成员,与VEGF-A不同,其表达与病理性血管生成和炎症选择性相关,阻断PlGF不影响健康血管。在糖尿病视网膜病变和新生血管性年龄相关性黄斑变性患者眼内液中PlGF水平升高,临床前模型显示抑制PlGF可减少新生血管、渗漏、炎症和胶质增生,且对CNV瘢痕的抑制作用独特。
要点
- PlGF表达与病理性血管生成和炎症相关,阻断PlGF不影响健康血管。
- DR和nvAMD患者房水、玻璃体或视网膜中PlGF水平升高。
- 临床前模型中抑制PlGF可减少新生血管、渗漏、炎症和胶质增生。
核心结论
- 临床前结果表明抗PlGF治疗可能优于抗VEGF治疗,可作为单独治疗或与抗VEGF联合应用。
- 仍需更多临床研究进一步阐明PlGF在眼病中的作用及其作为治疗靶点的潜力。
研究设计与样本
- 综述总结了PlGF及其受体系统在视网膜血管疾病中的临床前证据。
主要发现
- 在激光诱导CNV模型、氧诱导视网膜病变模型及多种小鼠糖尿病模型中,PlGF缺失或抑制可减少新生血管、视网膜渗漏、炎症和胶质增生,且不影响血管发育或诱导神经元变性。
- 在小鼠CNV模型中,PlGF阻断对视网膜瘢痕的抑制作用与多种VEGF抑制策略相比具有独特性。
关键数值与推荐
- DR和nvAMD患者房水、玻璃体和/或视网膜中PlGF水平升高。
临床怎么用
- 抗PlGF治疗可能作为单独治疗或与抗VEGF联合用于视网膜血管疾病,但尚需临床研究验证。
局限性
- 证据主要来自临床前研究,仍需额外临床研究进一步阐明PlGF的作用和治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family. Upon binding to VEGF- and neuropilin-receptor sub-types, PlGF modulates a range of neural, glial and vascular cell responses that are distinct from VEGF-A. As PlGF expression is selectively associated with pathological angiogenesis and inflammation, its blockade does not affect the healthy vasculature. PlGF actions have been extensively described in tumor biology but more recently there has been accumulating preclinical evidence that indicates that this growth factor could have an important role in retinal diseases. High levels of PlGF have been found in aqueous humor, vitreous and/or retina of patients exhibiting retinopathies, especially those with diabetic retinopathy (DR) and neovascular age-related macular degeneration (nvAMD). Expression of this growth factor seems to correlate closely with many of the key pathogenic features of early and late retinopathy in preclinical models. For example, studies using genetic modification and/or pharmacological treatment to block PlGF in the laser-induced choroidal neovascularization (CNV) model, oxygen-induced retinopathy model, as well as various murine diabetic models, have shown that PlGF deletion or inhibition can reduce neovascularization, retinal leakage, inflammation and gliosis, without affecting vascular development or inducing neuronal degeneration. Moreover, an inhibitory effect of PlGF blockade on retinal scarring in the mouse CNV model has also been recently demonstrated and was found to be unique for PlGF inhibition, as compared to various VEGF inhibition strategies. Together, these preclinical results suggest that anti-PlGF therapy might have advantages over anti-VEGF treatment, and that it may have clinical applications as a standalone treatment or in combination with anti-VEGF. Additional clinical studies are clearly needed to further elucidate the role of PlGF and its potential as a therapeutic target in ocular diseases.
引用
- Van Bergen T, Etienne I, Cunningham F, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2018. PMID: 30385175. doi:10.1016/j.preteyeres.2018.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。